- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Stada Launches Bevacizumab Biosimilar
Seeking to develop a biosimilar portfolio, Stada Arzneimittel has launched Oyavas in Germany and the Netherlands.
Stada Arzneimittel has received European Commission approval for the bevacizumab biosimilar Oyavas and has immediately launched the product in Germany and the Netherlands.
“Launches in other European countries will follow soon, depending in part on national pricing and reimbursement clearance,” the company said in a statement.
The launch is in partnership with mAbxience, which is an established biosimilar supplier in Latin America.
Stada, based in Bad Vilbel, Germany, said data submitted for the European marketing authorization demonstrated that the biosimilar is equivalent to the reference product (Avastin) in terms of quality, safety, and efficacy for the treatment of colon, rectal, breast, and non–small cell lung cancers, in addition to epithelial ovarian, fallopian tube, cervical, and primary peritoneal cancers.
“Through partnerships, STADA has built a comprehensive biosimilars portfolio and pipeline, not only in oncology, but also in therapeutic areas such as autoimmune disorders, osteoporosis, and ophthalmology, as the group continues to strengthen its presence in the specialty pharma sector, said Stada CEO Peter Goldschmidt.
Also of Note
mAbxience recently announced plans to strengthen its biosimilar production capacity in Leon, Spain.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Review Confirms Clinical Safety of Sandoz Denosumab Biosimilar vs Originator
December 11th 2024Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and clinical equivalence to reference denosumab (Prolia/Xgeva), supporting its approval and extrapolation to all approved indications.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Pertuzumab Biosimilar Shows Promise in HER2-Positive Breast Cancer Treatment
December 9th 2024The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in neoadjuvant treatment of HER2-positive, ER/PR-negative early or locally advanced breast cancer, offering a cost-effective alternative with comparable clinical outcomes.
Switching to Rituximab Biosimilars Is Safe, Effective for Patients With Oncohematological Diseases
December 5th 2024Patients with oncohematological diseases switching to rituximab biosimilars experienced similar safety and efficacy, highlighting biosimilars' potential for cost-effective treatment across various medical conditions.
